{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06052072",
            "orgStudyIdInfo": {
                "id": "CIP-002"
            },
            "organization": {
                "fullName": "Gradient Denervation Technologies",
                "class": "INDUSTRY"
            },
            "briefTitle": "Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)",
            "officialTitle": "Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)",
            "acronym": "PreVail-PH2",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "pulmonary-artery-denervation-clinical-study-using-the-gradient-denervation-system-in-heart-failure-patients-with-pulmonary-hypertension-group-prevail-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-02-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-02-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-18",
            "studyFirstSubmitQcDate": "2023-09-18",
            "studyFirstPostDateStruct": {
                "date": "2023-09-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Gradient Denervation Technologies",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUnapprovedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "This early feasibility study is intended to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension",
            "detailedDescription": "Gradient has developed a novel system for pulmonary artery denervation (PADN) to treat patients with heart failure who also developed pulmonary hypertension (PH). Pulmonary hypertension is frequently associated with left heart failure and is a strong independent predictor of clinical worsening and higher mortality. No therapeutic options are available to treat PH in this selected group of patients with heart failure. The objective is to improve exercise capacity and quality of life by targeting PH in these patients."
        },
        "conditionsModule": {
            "conditions": [
                "Group 2 Pulmonary Hypertension",
                "Heart Failure"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Prospective, single arm, multi-center, early feasibility study",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "PADN with Gradient Denervation System",
                    "type": "EXPERIMENTAL",
                    "description": "Procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.",
                    "interventionNames": [
                        "Device: Gradient Denervation System"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Gradient Denervation System",
                    "description": "Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.",
                    "armGroupLabels": [
                        "PADN with Gradient Denervation System"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Device and procedure related serious adverse events",
                    "description": "Number and frequency of serious adverse events deemed to be related to the investigational device and/or procedure.",
                    "timeFrame": "Through 30 days post-procedure"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in PVR",
                    "description": "Mean change from baseline in PVR",
                    "timeFrame": "Measured at 1- and 6- months post-procedure"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Heart Failure with EF \u2265 40% (by TTE within last 3 months)\n* Mean Pulmonary Artery Pressure (mPAP) \\>20 mmHg at rest\n* Pulmonary Vascular Resistance (PVR) \u2265 3WU at rest\n* Pulmonary Capillary Wedge Pressure \\> 15 mmHg (at rest) or \\> 18 with passive leg raise\n* Cardiac index (CI) \u2265 1.2 L/min/m2\n* NYHA Class II or III\n* Glomerular Filtration Rate (GFR) \u2265 25 ml/min\n* N-terminal pro-B-type natriuretic peptide (NT-proBNP) \u2265 400pg/mL\n* Stable, guideline directed medical treatment, including controlled volume status for a minimum of 3 months prior treatment\n\nExclusion Criteria:\n\n* Life expectancy of \\< 2 years\n* Inability to take dual antiplatelet or anticoagulants, hypersensitivity or allergy to aspirin or clopidogrel\n* Unable to tolerate right heart catheterization\n* Pulmonary artery aneurysm, moderate or greater PA stenosis or other PA anatomy that would prevent safe or proper use of the study device\n* Severe aortic, mitral or pulmonary valve regurgitation\n* Tricuspid regurgitation in conjunction with the presence of cirrhosis or congestive hepatopathy\n* Clot or Thrombus in any potential target ablation zone (right, left or main pulmonary artery)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "22 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Julie Messer",
                    "role": "CONTACT",
                    "phone": "763-657-7036",
                    "email": "clinical@gradientdenervation.com"
                }
            ],
            "locations": [
                {
                    "facility": "Duke University",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27708",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rose Burns",
                            "role": "CONTACT",
                            "email": "rose.burns@duke.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "University of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53705",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nicole Mildenstein",
                            "role": "CONTACT",
                            "email": "cvmstudyteam@medicine.wisc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006976",
                    "term": "Hypertension, Pulmonary"
                },
                {
                    "id": "D000006973",
                    "term": "Hypertension"
                },
                {
                    "id": "D000006333",
                    "term": "Heart Failure"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "asFound": "Heart Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "asFound": "Hypertension",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10027",
                    "name": "Hypertension, Pulmonary",
                    "asFound": "Pulmonary Hypertension",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                }
            ]
        }
    },
    "hasResults": false
}